Constitutive MAPK pathway activation in cancer can occur through several mechanisms, most frequently via mutations in BRAF or RAS. Activating NRAS and BRAF mutations are present in approximately 20% [6, 7] and 50% [6, 8] of primary cutaneous melanomas, respectively. This evidence concerns the gene BRAF and cutaneous melanoma.